朱小东, 成远, 李伟. 2023年ASCO肝胆胰恶性肿瘤治疗进展. 实用肿瘤杂志, 2023, 38(4): 324-331. Zhu Xiaodong, Cheng Yuan, Li Wei. Advances in treatment of hepatobiliary and pancreatic malignancies: Highlights from 2023 ASCO annual meeting. Journal of Pra...
2023 EAU/ASCO指南:阴茎癌(更新版) 下载积分: 1500 内容提示: Review – Penile CancerEuropean Association of Urology-American Society of ClinicalOncology Collaborative Guideline on Penile Cancer: 2023 UpdateOscar R. Brouwera, * , Maarten Albersen b , Arie Parnham c , Chris Protzel d , Curtis A...
phase 3 study DESTINY-Breast03. Abstract presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX. Abstract GS2-02.
ASCO Abstract No.: 9087 ASCO Poster Session: Lung Cancer – Non-Small Cell Metastatic Poster Session. Session Date & Time: Sunday June 4, 8:00 to 11:00am CT Summit Therapeutics’ Mission Statement To build a viable, long-lasting health care organization that assumes full responsibility for ...
I’m going to go with the abstract presented by Nizar Jacques Bahlis, MD, bringing venetoclax [Venclexta] back into the forefront of multiple myeloma treatment.1 I had [often] overlooked venetoclax in patients with t(11;14) myeloma and just gone with mo...
GB491 (Lerociclib) has garnered international recognition at the 2023 ASCO annual meeting, which was successfully held in Chicago from 2 June to 6 June 2023:The research results of the LEONARDA-1 study were announced in the poster discussion session of the Metastatic Breast Cancer session ...
研究阶段成果和临床进展。与ASCO等会议不同,AACR更加聚焦在临床早期以及临床前阶 段,更加体现与初探产品的未来潜力。伴随着中国国内创新药水平的不断提升,国内新药研 发已将目光和参与热情更多的聚焦于每年的AACR。 通过“智慧芽-新药情报库”,检索进入“转化医学”,学术会议选择“AACR2024”,可查询到 ...
一年一度的全球肿瘤学盛会——第59届2023年美国临床肿瘤学会(ASCO 2023)年会定于美国芝加哥当地时间2023年6月2日~6日正式拉开帷幕,包括 200 个口头报告研究(Oral abstract)、2000 +壁报展示(Poster session)、46 场临床科学研讨会(Clinical Science Symposium)等!
文献检索的外文数据库包括PubM ed、Embase和Cochrane Library,中文数据库包括中国知网(CNKI)和中国生物医学文献服务系统(SinoMed),会议论文摘要主要检索美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)和欧洲肿瘤内科学会(European Society for Medical Oncology,ESMO)官网,检索时限均为建库至2023年6月15日。
ASCO新见,T-DXd经治后抗HER2 TKI真实世界数据 2019年DESTINY-Breast 01研究数据公布后,T-DXd便获得美国食品药品监督管理局(FDA)批准用于HER2阳性晚期乳腺癌的三线及以后治疗。因此国外已积累了更多T-DXd经治后的真实世界的数据与经验。现将本次ASCO公布的两项真实世界研究予以分享,以期为我国临床实践提供参考。